# Differentiated medicines, discovered at record pace With our AI-enabled drug discovery platform and the dedication of our brilliant, hard-working team, we have discovered differentiated therapies for some of the most challenging and pervasive diseases — at record pace. We’re immensely proud of how far we’ve come since our founding in 2019. And we’re just getting started. ## Many Enveda molecules have already advanced into the clinic. Watch their progress. 3 Clinical Assets Across 4 Indications 6 IND-enabling Assets 17 Development Candidates #### ENV-294 **Mechanism:** Novel (Non-Kinase) **Indication:** Atopic Dermatitis **Phase:** 2a ENV-294 is a first-in-class, once-daily oral small molecule with a Dupi-like efficacy and safety profile, with pan-endotype potential in atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 has completed Phase 1b trials and has initiated Phase 2a trials in atopic dermatitis. #### ENV-294 **Mechanism:** Novel (Non-Kinase) **Indication:** Asthma **Phase:** 2a Demonstrating its pipeline-in-a-product potential, ENV-294 has initiated Phase 2a trials in asthma. #### ENV-308 **Mechanism:** Novel (Hormone Mimetic) **Indication:** Chronic Weight Maintenance **Phase:** 1 ENV-308 is a first-in-class, once-daily oral small molecule for chronic weight maintenance. ENV-308 promotes high-quality weight loss with muscle preservation. ENV-308 is currently in Phase 1 trials. #### ENV-6946 **Mechanism:** Novel (TL1A+ Pathway Inhibitor) **Indication:** Inflammatory Bowel Disease **Phase:** 1 ENV-6946 is a first-in-class, gut-preferred, once-daily oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ENV-6946 is currently in Phase 1 trials. # Featured Medicines ## ENV-294 A new way to counteract atopic dermatitis & other inflammatory diseases ##### THE PROBLEM Over 10% (30M+) of the US population suffers from atopic dermatitis, commonly known as eczema. Yet, today’s treatments for moderate-to-severe eczema either rely on injectables that pose a significant barrier to patient care or oral therapies that come with potentially serious toxicities. Moreover, despite these treatments, [half of all eczema to atopic dermatitis patients](https://nationaleczema.org/research/eczema-facts/) respond poorly to therapy. ##### THE MOLECULE We are developing a first-in-class medicine that fights inflammation in a new way. This novel mechanism allows it to exert potentially powerful anti-inflammatory effects without the same toxicities that have burdened previous treatments – and can be delivered orally via a pill. ##### THE PROGRESS Our molecule has demonstrated robust efficacy comparable to Jak-inhibitors in preclinical atopic dermatitis models but without their concomitant risks as evidenced by pre-clinical safety testing. It is currently in Phase 1b clinical trials. ## ENV-308 A new way to sustain weight loss & metabolic health ##### THE PROBLEM Obesity affects over 40% of adults in the United States and nearly 900 million adults globally. It is a primary driver of diabetes, cardiovascular disease, fatty liver disease, and reduced quality of life. While modern injectable therapies can induce substantial weight loss, they are difficult to sustain long-term due to tolerability, cost, access, and high discontinuation rates. Upon discontinuation, the majority of patients rapidly regain weight and lose metabolic benefits, leaving no effective solution for durable maintenance. ##### THE MOLECULE We are developing a first-in-class small-molecule medicine designed to support long-term metabolic balance. ENV-308 mimics an endogenous anti-obesity hormone, engaging central satiety and reward pathways while restoring metabolic sensitivity in obesity. This differentiated mechanism enables appetite regulation and metabolic control without relying on incretin signaling — and is designed for once-daily oral dosing suitable for chronic use. ##### THE PROGRESS ENV-308 has demonstrated sustained appetite suppression, steady body-weight loss, and complete prevention of weight regain following GLP-1 withdrawal in preclinical obesity models at any target weight, with weight loss driven predominantly by fat mass preservation. The molecule has shown a favorable safety and tolerability profile in IND-enabling studies and is advancing through Phase 1 trials in healthy and obese individuals. ## ENV-6946 A gut-preferred molecule for inflammatory bowel disease ##### THE PROBLEM Inflammatory bowel disease, or IBD, which includes both Crohn’s disease and Ulcerative Colitis, is a chronic autoimmune disorder that damages the digestive tract and disrupts the lives of more than [3 million](https://www.cdc.gov/mmwr/volumes/65/wr/mm6542a3.htm#T1_down) people in the United States. IBD has [limited treatment options](https://pmc.ncbi.nlm.nih.gov/articles/PMC10537095/) that have proven to cause long-term remission in patients. Moreover, many safe existing treatments have to be delivered as injections or pills that come with significant safety liabilities. ##### THE MOLECULE We are developing a new therapeutic approach to treating IBD. Our first-in-class molecule hits multiple clinically validated pathways simultaneously, has been engineered to be preferentially present in the gut, and can be administered as a convenient pill. With ESN-6946, we have the potential to deliver improved safety, efficacy, and convenience. ##### THE PROGRESS This powerful molecule is currently in Phase 1 trials. ## Be a part of our progress Today’s mission: drug discovery. Tomorrow’s possibilities: agriculture, nutrition, manufacturing, and more. Together, we can rapidly multiply humanity’s knowledge of the natural world’s chemistry and solve many of the greatest challenges in human and planetary health.